NCT02519348 2026-02-17
A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma
MedImmune LLC
Phase 2 Active not recruiting
Clinical Trials
119 trialsNCT03463876 2026-02-17
A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib in Patients With Advanced HCC(RESCUE)
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Completed
NCT03713593 2026-02-05
LEAP-002
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03298451 2026-01-14
HIMALAYA
AstraZeneca
Phase 3 Active not recruiting
NCT04573881 2026-01-12
#HOPE4LIVER
HistoSonics, Inc.
Phase NA Active not recruiting
NCT01658878 2025-12-24
CheckMate040
Bristol-Myers Squibb
Phase 1/2 Completed
NCT03755791 2025-12-11
COSMIC-312
Exelixis
Phase 3 Active not recruiting
NCT05256381 2025-11-17
A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors
Sotio Biotech Inc.
Phase 2 Terminated
NCT05091346 2025-10-24
A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors
Eisai Inc.
Phase 1/2 Completed
NCT03412773 2025-10-14
A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)
BeiGene
Phase 3 Completed
NCT03062358 2025-09-30
MK-3475-394
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT05104567 2025-09-24
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)
Sanofi
Phase 2 Completed
NCT04487067 2025-09-22
AMETHISTA
Hoffmann-La Roche
Phase 3 Completed
NCT03126110 2025-08-14
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Phase 1/2 Completed
NCT04696055 2025-05-13
Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint Inhibitors
Bayer
Phase 2 Completed
NCT04732286 2025-05-08
A Study of Atezolizumab in Combination With Bevacizumab in Spanish Patients With Unresectable or Unsuitable for Locoregional Treatments Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy
Hoffmann-La Roche
Phase 3 Terminated
NCT03783871 2025-04-25
NW
Ethicon, Inc.
Phase NA Completed
NCT04629339 2025-03-13
Study of INCB086550 in Select Solid Tumors
Incyte Corporation
Phase 2 Terminated
NCT04401800 2025-03-10
Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma
BeiGene
Phase 2 Completed
NCT05233098 2025-03-06
TheraSphere Post-Approval Study to Calculate the Radiation-absorbed Dose of Tc-99m MAA.
Boston Scientific Corporation
Completed
NCT02576509 2025-02-17
An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma
Bristol-Myers Squibb
Phase 3 Completed
NCT05848947 2025-01-29
MAApping
Sirtex Medical
Phase 4 Completed
NCT05653427 2025-01-13
A Study of Amivantamab Monotherapy in Participants With Previously Treated Advanced Hepatocellular Carcinoma
Janssen Research & Development, LLC
Phase 2 Terminated
NCT04338685 2024-12-09
A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases
Hoffmann-La Roche
Phase 1 Completed
NCT03474640 2024-11-22
Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies
TopAlliance Biosciences
Phase 1 Completed
NCT03419897 2024-10-26
Study of BGB-A317 in Participants With Previously Treated Unresectable HCC
BeiGene
Phase 2 Completed
NCT03941873 2024-10-26
A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer
BeiGene
Phase 1/2 Completed
NCT02325739 2024-10-21
FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression
Novartis
Phase 1/2 Completed
NCT00687596 2024-09-19
Study of TAC-101 as Second Line Treatment in Patients With Advanced Hepatocellular Carcinoma Who Received Sorafenib as First Line Therapy
Taiho Oncology, Inc.
Phase 2 Terminated
NCT02702414 2024-09-04
KEYNOTE-224
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT02112656 2024-08-20
OPTIMA
Imunon
Phase 3 Completed
NCT02509507 2024-08-06
MASTERKEY-318
Amgen
Phase 1/2 Completed
NCT03586050 2024-07-24
Study to Evaluate the Safety and Effectiveness of Microwave Ablation in Patients With Hepatocellular Carcinoma in Korea
Ethicon, Inc.
Phase NA Completed
NCT02314052 2024-07-11
Phase Ib/2, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Hepatocellular Carcinoma
Novo Nordisk A/S
Phase 1/2 Terminated
NCT03483922 2024-07-05
HCC Screening Using DNA Methylation Changes in ctDNA
HKGepitherapeutics
Completed
NCT00617981 2024-05-03
Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)
Imunon
Phase 3 Completed
NCT00940225 2024-04-25
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
Exelixis
Phase 2 Completed
NCT02705105 2024-04-25
Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors
Kyowa Kirin Co., Ltd.
Phase 1/2 Completed
NCT03890731 2024-04-02
A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been Completed
Bayer
Phase 2 Completed
NCT02329860 2024-01-22
Study of Apatinib After Systemic Therapy in Patients With Hepatocellular Carcinoma(AHELP)
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Completed
NCT03422679 2024-01-16
Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies
Cellestia Biotech AG
Phase 1/2 Terminated
NCT03006926 2023-12-13
A Trial of Lenvatinib Plus Pembrolizumab in Participants With Hepatocellular Carcinoma
Eisai Inc.
Phase 1 Completed
NCT00355238 2023-12-01
A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
Bristol-Myers Squibb
Phase 2 Completed
NCT03684811 2023-11-18
A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation
Novo Nordisk A/S
Phase 1/2 Completed
NCT02279719 2023-11-15
A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma
Sumitomo Pharma America, Inc.
Phase 1/2 Completed
NCT02834780 2023-11-13
Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma
Eisai Inc.
Phase 1 Completed
NCT03434379 2023-10-23
IMbrave150
Hoffmann-La Roche
Phase 3 Completed
NCT00699816 2023-07-11
Efficacy and Safety of Immuncell-LC Group and Non-treatment Group in Hepatocelluar Carcinoma Patients
GC Cell Corporation
Phase 3 Completed
NCT04194801 2023-02-06
A Phase Ib/II Study of Fisogatinib(BLU-554) in Subjects With Hepatocellular Carcinoma
CStone Pharmaceuticals
Phase 1/2 Completed
NCT02435433 2023-01-20
REACH-2
Eli Lilly and Company
Phase 3 Completed